The primary objective of this study was to evaluate safety and tolerability of ACZ885 in this
extension study. This extension study offered the opportunity for participants who completed
Epoch 4 of the preceding CACZ885N2301 (NCT02059291) study to continue to be treated with
ACZ885 until approval in Japan of the drug in Periodic Fever Syndromes or until development
of ACZ885 in Periodic Fever Syndromes was suspended.